Zacks Podcast Highlights: Immunotherapy Stocks 101: What Biotech Investors Need to Know Now
Eric Dutram
Updated
For Immediate Release
Chicago, IL – In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments. Brad specializes in the world of immunotherapy, a technique that is revolutionizing the cancer treatment market by harnessing the power of someone's immune system to fight disease. We get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look in 2017.
To listen to the podcast, click the link or check out the embeded podcast below: ( https://www.zacks.com/stock/news/239360/is-immunotherapy-the-next-hot-industry-for-biotech-stock-investors )
Biotechnology can be a tough market for investors to break in to. The jargon is intimidating, the volatility is incredible, and there are political concerns to be cognizant of as well.
But in this edition of the Dutram Report, I take a closer look at this market, and in particular the immunotherapy world, in order to shine some light on this promising space for investors. In order to do this, I talk with Brad Loncar, the CEO of Loncar Investments, who developed a benchmark of such companies called the Loncar Cancer Immunotherapy Index, which is the underlying benchmark for the Loncar Cancer Immunotherapy ETF (CNCR).
In the interview, we discuss the basics of immunotherapy, and why this technique might be a real gamechanger for the treatment of cancer. The approach looks to harness the power of someone’s immune system in order to fight disease, which may help some patients improve their quality of life while still achieving great outcomes. This only scratches the surface though, as we discuss some of the more innovative and groundbreaking treatments under development in this market too.
We also discuss how someone might go about investing in this market with stocks, and why a broad biotechnology ETF like IBB or XBI might not get you exposure to this corner of the sector. We also take a deeper look at the Loncar index, and what exactly an ‘immunotherapy stock’ means.
In particular, I note some of the large caps which find their way into the benchmark, such as Amgen (AMGN), Merck (MRK), or AstraZeneca (AZN). But we also discuss some of the more growth-oriented names that might be more in-line with investors’ initial assumptions about the market, such as KITE Pharma (KITE) or Juno Therapeutics (JUNO). These all fit into the theme in their own way though, and we dive into the key trends taking place in these companies (and others) that have business in this important market.
Lastly, I also wanted to note that Loncar has partnered with the Cancer Research Institute, and will be giving part of its fee to the charity. Loncar Investments looks to give four basis points of the fee from assets under management to the CRI on a regular basis, in an effort to help support this basic research institution. This is definitely something that could be more of a trend in the future, and especially among the many socially-conscious ETFs out there.
This was certainly an informative podcast, and I definitely learned something about this often-overlooked corner of the biotechnology world. I think you will as well, so make sure to listen to this edition of the Dutram Report for additional information. And for more news and insights into the world of ETFs, make sure to be on the lookout for the next edition of the Dutram Report, and check out the many other great Zacks podcasts as well!
Want More of Our Best Recommendations?
Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential .
Learn More>>
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros .
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
